Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001208 · ClinicalTrials.gov registry record
Botulinum Toxin for the Treatment of Involuntary Movement Disorders
A clinical trial of Movement Disorders, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT00001208: Recruiting study of Movement Disorders, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
NCT00001208 is a study of Movement Disorders that is actively recruiting participants, run by National Institute of Neurological Disorders and Stroke (NINDS). The registered enrollment target is 2,000 participants, above the 990-participant average among 26 other Movement Disorders trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001208, a study of Movement Disorders, is actively recruiting participants, sponsored by National Institute of Neurological Disorders and Stroke (NINDS).
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
BTX has been used since the 1980s in support of the research mission of NINDS. Initial studies were focused on expanding the applicability of BTX treatment to movement disorders and exploring new indications. We evaluated the efficacy of an alternative serotype, type F. Under other protocols, we continue to study the physiology of movement disorders and BTX response. The application of BTX therapy to movement disorders requires an understanding of BTX preparation and handling. The treatment must be tailored to the disorder under treatment and to its expression in the individual patient. Users must know the specific techniques of injection, including the use of EMG and ultrasound guidance. This protocol allows us to train physicians in all aspects of the use of BTX. It also provides us with a cohort of patients, receiving a standard method of treatment and with a stable response to BTX injection, for participation in other protocols on movement disorders and on the responses to BTX injection.
Primary Outcome
Data regarding the movement disorder of the subject and observations of their standard treatment will be collected. Data may be used for future research questions that are related to subjects movement disorder and/or treatment.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 1989-10-26 |
What NCT00001208 shows while recruiting
NCT00001208 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 990-participant average among 26 other Movement Disorders trials with a reported enrollment target (102% higher).
The record links to 1 condition, with Movement Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT00001208 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00001208 about?
NCT00001208 is a clinical study titled "Botulinum Toxin for the Treatment of Involuntary Movement Disorders". BTX has been used since the 1980s in support of the research mission of NINDS. Initial studies were focused on expanding the applicability of BTX treatment to movement disorders and exploring new indications. We evaluated the efficacy of an alternative serotype, type F. Under other protocols, we con...
What is the current status of trial NCT00001208?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 1989-10-26.
What conditions does trial NCT00001208 study?
This clinical trial studies the following conditions: Movement Disorders.
Who is sponsoring clinical trial NCT00001208?
This trial is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), which has 567 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001208 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Movement Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00001208's enrollment target sits among peer trials
2,000 2nd of 26 the highest of 26 other Movement Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Movement Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
RECRUITING
-
Neurophysiology of the Basal Ganglia, Thalamus, and Cerebellum in Patients With Movement Disorders
RECRUITING · NA
-
A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications
RECRUITING
-
Abbott DBS Post-Market Study of Outcomes for Indications Over Time
RECRUITING
-
Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures
RECRUITING
-
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI